Vanda Pharmaceuticals Inc (LTS:0LKB)
$ 5.0312 -0.1487 (-2.87%) Market Cap: 293.87 Mil Enterprise Value: -74.45 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 64/100

Q4 2022 Vanda Pharmaceuticals Inc Earnings Call Transcript

Feb 08, 2023 / 09:30PM GMT
Release Date Price: $10.39
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Vanda Pharmaceuticals Inc. Earnings Conference Call. I would now like to turn the call over to Kevin Moran, Vanda's Chief Financial Officer. Please go ahead.

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer

Thank you, Mandy. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals' Fourth Quarter and Full Year 2022 Performance. Our fourth quarter and full year 2022 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.

Joining me on today's call is Dr. Mihales Polymeropoulos, our President, Chief Executive Officer and Chairman of the Board; and Tim Williams, our General Counsel.

Following my introductory remarks, Mihales will update you on our ongoing activities. I will then comment on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot